Lupin
Lupin
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return279%
-
Sales Growth22%
-
Return on Equity30 %
Why Super 50
India's third largest pharmaceutical company by sales has not only grown consistently but has also maintained its profitability. Lupin, which had stayed away from acquisitions for a while, is now scouting for deals to improve its presence in Europe and in the complex generics segment.
